SAB3500346
Anti-ACE2 antibody produced in rabbit
affinity isolated antibody, buffered aqueous solution
Synonym(e):
Anti-ACE2
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(3)
About This Item
UNSPSC-Code:
12352203
NACRES:
NA.41
Empfohlene Produkte
Biologische Quelle
rabbit
Qualitätsniveau
Konjugat
unconjugated
Antikörperform
affinity isolated antibody
Antikörper-Produkttyp
primary antibodies
Klon
polyclonal
Form
buffered aqueous solution
Speziesreaktivität
mouse, human
Methode(n)
immunofluorescence: suitable
immunohistochemistry: suitable
indirect ELISA: suitable
western blot: suitable
NCBI-Hinterlegungsnummer
UniProt-Hinterlegungsnummer
Versandbedingung
dry ice
Lagertemp.
−20°C
Posttranslationale Modifikation Target
unmodified
Angaben zum Gen
human ... ACE2(59272)
Allgemeine Beschreibung
Angiotensin-converting enzyme-2 (ACE2), is a membrane-associated and secreted enzyme, encoded by the gene mapped to human chromosome Xp22.2. Ace 2 is a human homolog of ACE and is expressed mainly on vascular endothelium of heart, kidney, and testis. Ace2 structure comprises a N-terminal PD and a C-terminal collectrin-like domain (CLD).
Immunogen
ACE2 antibody was raised against a synthetic peptide corresponding to amino acids near the center of human ACE2.
Biochem./physiol. Wirkung
Angiotensin-converting enzyme-2 (ACE2) catalyzes the conversion of Ang I to Ang1-9. It might also be involved in maintaining the balance of local renin-angiotensin system (RAS) in heart and kidney. Ace 2 acts as a functional receptor for spike glycoprotein of severe acute respiratory syndrome-coronavirus (SARS-CoV) and the new coronavirus (SARS-CoV-2), which is a causative agent for coronavirus disease 2019 (COVID-19). Downregulated expression of Ace 2 causes cardiovascular diseases.
Leistungsmerkmale und Vorteile
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Verlinkung
The action of this antibody can be blocked using blocking peptide SBP3500346.
Physikalische Form
Supplied in PBS with 0.02% sodium azide.
Haftungsausschluss
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Sie haben nicht das passende Produkt gefunden?
Probieren Sie unser Produkt-Auswahlhilfe. aus.
Empfehlung
Produkt-Nr.
Beschreibung
Preisangaben
Ähnliches Produkt
Produkt-Nr.
Beschreibung
Preisangaben
Lagerklassenschlüssel
10 - Combustible liquids
WGK
WGK 2
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Kunden haben sich ebenfalls angesehen
Lin Wang et al.
Theranostics, 11(2), 649-664 (2021-01-05)
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide epidemic of the lethal respiratory coronavirus disease (COVID-19), necessitating urgent development of specific and effective therapeutic tools. Among several therapeutic targets of coronaviruses, the spike protein is
Clara Husser et al.
Microorganisms, 12(3) (2024-03-28)
While having already killed more than 7 million of people worldwide in 4 years, SARS-CoV-2, the etiological agent of COVID-19, is still circulating and evolving. Understanding the pathogenesis of the virus is of capital importance. It was shown that in
Elisa Avolio et al.
Clinical science (London, England : 1979), 135(24), 2667-2689 (2021-11-23)
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a broad range of clinical responses including prominent microvascular damage. The capacity of SARS-CoV-2 to infect vascular cells is still debated. Additionally, the SARS-CoV-2 Spike (S) protein may act as a
Shine Varghese Jancy et al.
Biological procedures online, 25(1), 22-22 (2023-07-27)
The entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the host cell is mediated through the binding of the SARS-CoV-2 Spike protein via the receptor binding domain (RBD) to human angiotensin-converting enzyme 2 (hACE2). Identifying compounds that inhibit
Lai-Keng Loi et al.
Heliyon, 9(12), e22614-e22614 (2023-12-18)
The entry of SARS-CoV-2 into host cells involves the interaction between the viral spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor. Given that the spike protein evolves rapidly to evade host immunity, therapeutics that block ACE2 accessibility, such
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.